Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 19, Number 8—August 2013

Perspective

Norovirus Disease in the United States

Aron J. HallComments to Author , Ben A. Lopman, Daniel C. Payne, Manish M. Patel, Paul A. Gastañaduy, Jan Vinjé, and Umesh D. Parashar
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 2

Population-based rates of norovirus disease–associated outcomes across all age groups by outcome*

Outcome Study (reference) Country Rate/10,000 population (uncertainty bounds)†
Deaths Scallan et al. (6) United States 0.019 (0.011–0.029)
Hall et al. (9) United States 0.027 (0.023–0.031)

Verhoef et al. (13)
The Netherlands
0.040 (0.020–0.070)
Hospitalizations Scallan et al. (6) United States 1.9 (1.1–2.9)
Lopman et al. (10) United States 2.4 (NR)

Verhoef et al. (13)
The Netherlands
1.2 (0.5–2)
Emergency department visits
Gastañaduy et al. (11)
United States
13.5 (8.0–18.9)
Outpatient visits Hall et al. (7) United States 64.0 (36.0–120.0)
Gastañaduy et al. (11) United States 57.0 (40.0–74)
Verhoef et al. (13) The Netherlands 92.0 (50.0–150)
Phillips et al. (14) United Kingdom 54.0 (48.0–60)
Tam et al. (15) United Kingdom 21.0 (14.0–30)

Karsten et al. (16)
Germany
63.0 (29.0–107)
Total illnesses Scallan et al. (6) United States 698.0 (430.0–1,028)
Hall et al. (7) United States 650.0 (370.0–1,200)
Verhoef et al. (13) The Netherlands 380.0 (264.0–544)
Phillips et al. (14) United Kingdom 450.0 (380.0–520)
Tam et al. (15) United Kingdom 470.0 (391.0–565)
Thomas et al. (17) Canada 1,040.0 (924.0–1,163)

*NR, not reported.
†Uncertainty bounds represent 95% CIs for all studies, except for Scallan at al. (6), Hall et al. (7), and Thomas et al. (17), who used 90% credible intervals.

Main Article

TOP